Key clinical point: Severe atopic dermatitis (AD) is associated with an almost 2-fold higher risk for depression and internalizing behavior in early childhood.

Major finding: Children with vs. without severe AD were more prone to experience depressive (adjusted odds ratio [aOR], 2.38; 95% confidence interval [CI], 1.21-4.72) and internalizing (aOR, 1.90; 95% CI, 1.14-3.16) symptoms.

Study details: Findings are from a longitudinal, population-based birth cohort study including 11,181 children who were followed up from birth for a mean duration of 10 years.

Disclosures: This study was funded by Wellcome Trust, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Center for Advancing Translational Sciences, and National Institutes of Health. Dr. Wan and Dr. Abuabara declared receiving research funding from Pfizer.

Source: Kern C et al. JAMA Dermatol. 2021 Sep 1. doi: 10.1001/jamadermatol.2021.2657.

Key clinical point: Severe atopic dermatitis (AD) is associated with an almost 2-fold higher risk for depression and internalizing behavior in early childhood.

Major finding: Children with vs. without severe AD were more prone to experience depressive (adjusted odds ratio [aOR], 2.38; 95% confidence interval [CI], 1.21-4.72) and internalizing (aOR, 1.90; 95% CI, 1.14-3.16) symptoms.

Study details: Findings are from a longitudinal, population-based birth cohort study including 11,181 children who were followed up from birth for a mean duration of 10 years.

Disclosures: This study was funded by Wellcome Trust, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Center for Advancing Translational Sciences, and National Institutes of Health. Dr. Wan and Dr. Abuabara declared receiving research funding from Pfizer.

Source: Kern C et al. JAMA Dermatol. 2021 Sep 1. doi: 10.1001/jamadermatol.2021.2657.

Key clinical point: Severe atopic dermatitis (AD) is associated with an almost 2-fold higher risk for depression and internalizing behavior in early childhood.

Major finding: Children with vs. without severe AD were more prone to experience depressive (adjusted odds ratio [aOR], 2.38; 95% confidence interval [CI], 1.21-4.72) and internalizing (aOR, 1.90; 95% CI, 1.14-3.16) symptoms.

Study details: Findings are from a longitudinal, population-based birth cohort study including 11,181 children who were followed up from birth for a mean duration of 10 years.

Disclosures: This study was funded by Wellcome Trust, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Center for Advancing Translational Sciences, and National Institutes of Health. Dr. Wan and Dr. Abuabara declared receiving research funding from Pfizer.

Source: Kern C et al. JAMA Dermatol. 2021 Sep 1. doi: 10.1001/jamadermatol.2021.2657.

Key clinical point: The combination of oral abrocitinib and topical therapy was effective and well tolerated in adolescents with moderate-to-severe atopic dermatitis (AD).

Major finding: At week 12, a significantly higher proportion of patients treated with abrocitinib 200 mg or 100 mg vs placebo achieved an Investigator’s Global Assessment response of 0/1 (46.2% and 41.6% vs 24.5%) and 75% or more improvement in Eczema Area and Severity Index (72.0% and 68.5% vs 41.5%; P < .05 for all). Serious adverse events were reported by less than 3% of patients.

Study details: Findings are from JADE TEEN, a phase 3 trial including 285 adolescents with moderate-to-severe AD and an inadequate response to topical medication or in need for systemic therapy, who were randomly assigned to receive once-daily oral abrocitinib, 200 mg or 100 mg, or placebo for 12 weeks in combination with topical therapy.

Disclosures: This study was funded by Pfizer Inc. The authors declared receiving nonfinancial support, grants, and personal fees from several sources including Pfizer. Four authors reported being employees and/or shareholders of Pfizer.

Source: Eichenfield LF et al. JAMA Dermatol. 2021 Aug 18. doi: 10.1001/jamadermatol.2021.2830.

Key clinical point: The combination of oral abrocitinib and topical therapy was effective and well tolerated in adolescents with moderate-to-severe atopic dermatitis (AD).

Major finding: At week 12, a significantly higher proportion of patients treated with abrocitinib 200 mg or 100 mg vs placebo achieved an Investigator’s Global Assessment response of 0/1 (46.2% and 41.6% vs 24.5%) and 75% or more improvement in Eczema Area and Severity Index (72.0% and 68.5% vs 41.5%; P < .05 for all). Serious adverse events were reported by less than 3% of patients.

Study details: Findings are from JADE TEEN, a phase 3 trial including 285 adolescents with moderate-to-severe AD and an inadequate response to topical medication or in need for systemic therapy, who were randomly assigned to receive once-daily oral abrocitinib, 200 mg or 100 mg, or placebo for 12 weeks in combination with topical therapy.

Disclosures: This study was funded by Pfizer Inc. The authors declared receiving nonfinancial support, grants, and personal fees from several sources including Pfizer. Four authors reported being employees and/or shareholders of Pfizer.

Source: Eichenfield LF et al. JAMA Dermatol. 2021 Aug 18. doi: 10.1001/jamadermatol.2021.2830.

Key clinical point: The combination of oral abrocitinib and topical therapy was effective and well tolerated in adolescents with moderate-to-severe atopic dermatitis (AD).

Major finding: At week 12, a significantly higher proportion of patients treated with abrocitinib 200 mg or 100 mg vs placebo achieved an Investigator’s Global Assessment response of 0/1 (46.2% and 41.6% vs 24.5%) and 75% or more improvement in Eczema Area and Severity Index (72.0% and 68.5% vs 41.5%; P < .05 for all). Serious adverse events were reported by less than 3% of patients.

Study details: Findings are from JADE TEEN, a phase 3 trial including 285 adolescents with moderate-to-severe AD and an inadequate response to topical medication or in need for systemic therapy, who were randomly assigned to receive once-daily oral abrocitinib, 200 mg or 100 mg, or placebo for 12 weeks in combination with topical therapy.

Disclosures: This study was funded by Pfizer Inc. The authors declared receiving nonfinancial support, grants, and personal fees from several sources including Pfizer. Four authors reported being employees and/or shareholders of Pfizer.

Source: Eichenfield LF et al. JAMA Dermatol. 2021 Aug 18. doi: 10.1001/jamadermatol.2021.2830.

Key clinical point: Among hepatitis B virus-positive HCC patients, the 2-year recurrence-free survival rate was higher in those with negative expression of cytokeratin 19 compared to those who were CK19-positive. 

Major finding: In a multivariate analysis, CK19 expression was significantly associated with poor recurrence-free survival (hazard ratio 1.586, P = 0.042); other independent predictors were postoperative platelet > 300/L (HR 2.82), satellite nodule (HR = 1.71), 95 microvascular invasion (HR = 1.61), and tumor without capsule (HR 1.87).

Study details: The data come from a retrospective study of 674 adults with hepatitis B virus (HBV) positive hepatocellular carcinoma who underwent resection between January 2010 and May 2020. Researchers used a multivariate analysis to create a nomogram of 2-year recurrence-free survival.

Disclosures: The study was supported by the Gansu Science and Technology Department. The researchers had no financial conflicts to disclose.

Source: Shuyao W et al. J Gastrointest Surg. 2021 Sep 10. doi: 10.1007/s11605-021-05107-w.

Key clinical point: Among hepatitis B virus-positive HCC patients, the 2-year recurrence-free survival rate was higher in those with negative expression of cytokeratin 19 compared to those who were CK19-positive. 

Major finding: In a multivariate analysis, CK19 expression was significantly associated with poor recurrence-free survival (hazard ratio 1.586, P = 0.042); other independent predictors were postoperative platelet > 300/L (HR 2.82), satellite nodule (HR = 1.71), 95 microvascular invasion (HR = 1.61), and tumor without capsule (HR 1.87).

Study details: The data come from a retrospective study of 674 adults with hepatitis B virus (HBV) positive hepatocellular carcinoma who underwent resection between January 2010 and May 2020. Researchers used a multivariate analysis to create a nomogram of 2-year recurrence-free survival.

Disclosures: The study was supported by the Gansu Science and Technology Department. The researchers had no financial conflicts to disclose.

Source: Shuyao W et al. J Gastrointest Surg. 2021 Sep 10. doi: 10.1007/s11605-021-05107-w.

Key clinical point: Among hepatitis B virus-positive HCC patients, the 2-year recurrence-free survival rate was higher in those with negative expression of cytokeratin 19 compared to those who were CK19-positive. 

Major finding: In a multivariate analysis, CK19 expression was significantly associated with poor recurrence-free survival (hazard ratio 1.586, P = 0.042); other independent predictors were postoperative platelet > 300/L (HR 2.82), satellite nodule (HR = 1.71), 95 microvascular invasion (HR = 1.61), and tumor without capsule (HR 1.87).

Study details: The data come from a retrospective study of 674 adults with hepatitis B virus (HBV) positive hepatocellular carcinoma who underwent resection between January 2010 and May 2020. Researchers used a multivariate analysis to create a nomogram of 2-year recurrence-free survival.

Disclosures: The study was supported by the Gansu Science and Technology Department. The researchers had no financial conflicts to disclose.

Source: Shuyao W et al. J Gastrointest Surg. 2021 Sep 10. doi: 10.1007/s11605-021-05107-w.

Key clinical point: The development of treatment-related adverse events was significantly correlated with improve overall and progression-free survival in HCC patients treated with ICI monotherapy in clinical trials.

Major finding: Treatment-related adverse events were reported in 56% of patients with unresectable or advanced HCC; the development of adverse events was associated with longer overall survival and progression-free survival rates compared to patients who did not develop treatment-related adverse events (16.7 months vs 11.2 months; 5.5 months vs 2.2 months, respectively).

Study details: The data come from a cohort of 406 adults with unresectable or advanced HCC who were receiving immune checkpoint inhibitor (ICI) therapy while enrolled in clinical trials submitted to the Food and Drug Administration.

Disclosures: The study received no outside funding. Lead author Dr. Pinato disclosed lecture fees from ViiV Healthcare, and Bayer Healthcare; travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, AstraZeneca; and research funding (to his institution) from MSD and BMS.

Source: Pinato DJ et al. Eur J Cancer. 2021 Sep 8. doi: 10.1016/j.ejca.2021.08.020. 

Key clinical point: The development of treatment-related adverse events was significantly correlated with improve overall and progression-free survival in HCC patients treated with ICI monotherapy in clinical trials.

Major finding: Treatment-related adverse events were reported in 56% of patients with unresectable or advanced HCC; the development of adverse events was associated with longer overall survival and progression-free survival rates compared to patients who did not develop treatment-related adverse events (16.7 months vs 11.2 months; 5.5 months vs 2.2 months, respectively).

Study details: The data come from a cohort of 406 adults with unresectable or advanced HCC who were receiving immune checkpoint inhibitor (ICI) therapy while enrolled in clinical trials submitted to the Food and Drug Administration.

Disclosures: The study received no outside funding. Lead author Dr. Pinato disclosed lecture fees from ViiV Healthcare, and Bayer Healthcare; travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, AstraZeneca; and research funding (to his institution) from MSD and BMS.

Source: Pinato DJ et al. Eur J Cancer. 2021 Sep 8. doi: 10.1016/j.ejca.2021.08.020. 

Key clinical point: The development of treatment-related adverse events was significantly correlated with improve overall and progression-free survival in HCC patients treated with ICI monotherapy in clinical trials.

Major finding: Treatment-related adverse events were reported in 56% of patients with unresectable or advanced HCC; the development of adverse events was associated with longer overall survival and progression-free survival rates compared to patients who did not develop treatment-related adverse events (16.7 months vs 11.2 months; 5.5 months vs 2.2 months, respectively).

Study details: The data come from a cohort of 406 adults with unresectable or advanced HCC who were receiving immune checkpoint inhibitor (ICI) therapy while enrolled in clinical trials submitted to the Food and Drug Administration.

Disclosures: The study received no outside funding. Lead author Dr. Pinato disclosed lecture fees from ViiV Healthcare, and Bayer Healthcare; travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, AstraZeneca; and research funding (to his institution) from MSD and BMS.

Source: Pinato DJ et al. Eur J Cancer. 2021 Sep 8. doi: 10.1016/j.ejca.2021.08.020. 

Key clinical point: Risk factors for secondary primary malignancies in HCC patients included older age at diagnosis, localized disease, smaller tumor size, and treatment with local tumor destruction, hepatectomy, and transplantation.   

Major finding: A total of 1,593 HCC patients (3.95%) developed secondary primary malignancies starting at 2 months after their initial HCC diagnoses; the top five sites were lung and bronchus; prostate, non-hodgkin lymphoma, colon, and breast.

Study details: The data come from a retrospective study of 40,314 adults with hepatocellular carcinoma who were diagnosed between 2000 and 2014 and identified through the SEER database who were followed for a median of 19 months from their initial HCC diagnoses.

Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.

Source: Kong J et al. Front Oncol. 2021 Aug 23. doi: 10.3389/fonc.2021.713637. 

Key clinical point: Risk factors for secondary primary malignancies in HCC patients included older age at diagnosis, localized disease, smaller tumor size, and treatment with local tumor destruction, hepatectomy, and transplantation.   

Major finding: A total of 1,593 HCC patients (3.95%) developed secondary primary malignancies starting at 2 months after their initial HCC diagnoses; the top five sites were lung and bronchus; prostate, non-hodgkin lymphoma, colon, and breast.

Study details: The data come from a retrospective study of 40,314 adults with hepatocellular carcinoma who were diagnosed between 2000 and 2014 and identified through the SEER database who were followed for a median of 19 months from their initial HCC diagnoses.

Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.

Source: Kong J et al. Front Oncol. 2021 Aug 23. doi: 10.3389/fonc.2021.713637. 

Key clinical point: Risk factors for secondary primary malignancies in HCC patients included older age at diagnosis, localized disease, smaller tumor size, and treatment with local tumor destruction, hepatectomy, and transplantation.   

Major finding: A total of 1,593 HCC patients (3.95%) developed secondary primary malignancies starting at 2 months after their initial HCC diagnoses; the top five sites were lung and bronchus; prostate, non-hodgkin lymphoma, colon, and breast.

Study details: The data come from a retrospective study of 40,314 adults with hepatocellular carcinoma who were diagnosed between 2000 and 2014 and identified through the SEER database who were followed for a median of 19 months from their initial HCC diagnoses.

Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.

Source: Kong J et al. Front Oncol. 2021 Aug 23. doi: 10.3389/fonc.2021.713637. 

Key clinical point: Raltitrexed-based transcatheter arterial chemoembolization (TACE) extended the overall survival of intermediate and advanced HCC patients in a real-world clinical setting.

Major finding: After propensity score matching, the overall survival rates at 6 months, 1 year, and 2 years were significantly higher in patients given raltitrexed compared to controls (78.2% vs 60.9%; 43.5% vs 22.8%; and 17.4% vs 2.2%, respectively).

Study details: The data come from HCC patients seen at multiple centers in Chongqing, China, between January 2013 and December 2019. Cases were divided into two groups based on treatment: the raltitrexed group (raltitrexed plus lobaplatin + pirarubicin) and the control group (lobaplatin + pirarubicin).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: He J et al. Hepatol Res. 2021 Sep 7. doi: 10.1111/hepr.13708. 

Key clinical point: Raltitrexed-based transcatheter arterial chemoembolization (TACE) extended the overall survival of intermediate and advanced HCC patients in a real-world clinical setting.

Major finding: After propensity score matching, the overall survival rates at 6 months, 1 year, and 2 years were significantly higher in patients given raltitrexed compared to controls (78.2% vs 60.9%; 43.5% vs 22.8%; and 17.4% vs 2.2%, respectively).

Study details: The data come from HCC patients seen at multiple centers in Chongqing, China, between January 2013 and December 2019. Cases were divided into two groups based on treatment: the raltitrexed group (raltitrexed plus lobaplatin + pirarubicin) and the control group (lobaplatin + pirarubicin).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: He J et al. Hepatol Res. 2021 Sep 7. doi: 10.1111/hepr.13708. 

Key clinical point: Raltitrexed-based transcatheter arterial chemoembolization (TACE) extended the overall survival of intermediate and advanced HCC patients in a real-world clinical setting.

Major finding: After propensity score matching, the overall survival rates at 6 months, 1 year, and 2 years were significantly higher in patients given raltitrexed compared to controls (78.2% vs 60.9%; 43.5% vs 22.8%; and 17.4% vs 2.2%, respectively).

Study details: The data come from HCC patients seen at multiple centers in Chongqing, China, between January 2013 and December 2019. Cases were divided into two groups based on treatment: the raltitrexed group (raltitrexed plus lobaplatin + pirarubicin) and the control group (lobaplatin + pirarubicin).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: He J et al. Hepatol Res. 2021 Sep 7. doi: 10.1111/hepr.13708. 

Key clinical point: The postoperative controlling nutritional status (PoCONUT) score was an independent predictor of both overall survival and recurrence-free survival in small HCC patients who underwent liver resection; higher scores were associated with decreased survival.

Major finding: Overall survival at 1, 3, and 5 years was 95.4 %, 81.2, and 63.3 %, respectively, in the low PoCONUT group, vs 88.7 %, 63.0, and 44.2 %, respectively, in the high PoCONUT group (P = 0.009). Similarly, recurrence-free survival at 1, 3, and 5 years was 80.4 %, 57.5, and 49.5 %, respectively, vs 66.1 %, 40.3%, and 31.0 %, respectively, in the low and high groups.

Study details: The data come from a retrospective, case-control study including 547 consecutive adult patients with small HCC who underwent liver resection between February 2007 and December 2015; patients were divided into low (382 patients) and high (165 patients) groups according to postoperative controlling nutritional status (PoCONUT) scores (2 or less; 3 or greater).

Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.

Source: Peng W et al. BMC Surg. 2021 Sep 7. doi: 10.1186/s12893-021-01334-9.

Key clinical point: The postoperative controlling nutritional status (PoCONUT) score was an independent predictor of both overall survival and recurrence-free survival in small HCC patients who underwent liver resection; higher scores were associated with decreased survival.

Major finding: Overall survival at 1, 3, and 5 years was 95.4 %, 81.2, and 63.3 %, respectively, in the low PoCONUT group, vs 88.7 %, 63.0, and 44.2 %, respectively, in the high PoCONUT group (P = 0.009). Similarly, recurrence-free survival at 1, 3, and 5 years was 80.4 %, 57.5, and 49.5 %, respectively, vs 66.1 %, 40.3%, and 31.0 %, respectively, in the low and high groups.

Study details: The data come from a retrospective, case-control study including 547 consecutive adult patients with small HCC who underwent liver resection between February 2007 and December 2015; patients were divided into low (382 patients) and high (165 patients) groups according to postoperative controlling nutritional status (PoCONUT) scores (2 or less; 3 or greater).

Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.

Source: Peng W et al. BMC Surg. 2021 Sep 7. doi: 10.1186/s12893-021-01334-9.

Key clinical point: The postoperative controlling nutritional status (PoCONUT) score was an independent predictor of both overall survival and recurrence-free survival in small HCC patients who underwent liver resection; higher scores were associated with decreased survival.

Major finding: Overall survival at 1, 3, and 5 years was 95.4 %, 81.2, and 63.3 %, respectively, in the low PoCONUT group, vs 88.7 %, 63.0, and 44.2 %, respectively, in the high PoCONUT group (P = 0.009). Similarly, recurrence-free survival at 1, 3, and 5 years was 80.4 %, 57.5, and 49.5 %, respectively, vs 66.1 %, 40.3%, and 31.0 %, respectively, in the low and high groups.

Study details: The data come from a retrospective, case-control study including 547 consecutive adult patients with small HCC who underwent liver resection between February 2007 and December 2015; patients were divided into low (382 patients) and high (165 patients) groups according to postoperative controlling nutritional status (PoCONUT) scores (2 or less; 3 or greater).

Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.

Source: Peng W et al. BMC Surg. 2021 Sep 7. doi: 10.1186/s12893-021-01334-9.

Key clinical point: HCC patients who underwent hepatic resection had significantly higher rates of overall survival and recurrence-free survival compared to those who underwent percutaneous ablation.

Major finding: Overall survival at 1, 3, and 5 years was 97.6%, 83.6%, and 71.5%, respectively, for the hepatic resection patients, vs 89.4%, 58.5%, and 48.8%, respectively, for the percutaneous ablation patients (P = 0.032). Recurrence-free survival at these time points was 77.6%, 47.9%, and 42.6%, respectively, for the hepatic resection group, and 40.5%, 23.2%, and 15.4%, respectively, for the percutaneous ablation group (P = 0.010). 

Study details: The data come from a retrospective study of 67 adults with resectable caudate HCC within Milan criteria at three centers; 46 underwent hepatic resection and 21 underwent percutaneous ablation.

Disclosures: The study was supported by the National Science Fund for Distinguished Young Scholars, the National Natural Science Foundation of China, and the Natural Science Foundation of Guangdong, China.

Source: Xie W et al. J Gastrointest Surg. 2021 Sep 7. doi: 10.1007/s11605-021-05111-0.

Key clinical point: HCC patients who underwent hepatic resection had significantly higher rates of overall survival and recurrence-free survival compared to those who underwent percutaneous ablation.

Major finding: Overall survival at 1, 3, and 5 years was 97.6%, 83.6%, and 71.5%, respectively, for the hepatic resection patients, vs 89.4%, 58.5%, and 48.8%, respectively, for the percutaneous ablation patients (P = 0.032). Recurrence-free survival at these time points was 77.6%, 47.9%, and 42.6%, respectively, for the hepatic resection group, and 40.5%, 23.2%, and 15.4%, respectively, for the percutaneous ablation group (P = 0.010). 

Study details: The data come from a retrospective study of 67 adults with resectable caudate HCC within Milan criteria at three centers; 46 underwent hepatic resection and 21 underwent percutaneous ablation.

Disclosures: The study was supported by the National Science Fund for Distinguished Young Scholars, the National Natural Science Foundation of China, and the Natural Science Foundation of Guangdong, China.

Source: Xie W et al. J Gastrointest Surg. 2021 Sep 7. doi: 10.1007/s11605-021-05111-0.

Key clinical point: HCC patients who underwent hepatic resection had significantly higher rates of overall survival and recurrence-free survival compared to those who underwent percutaneous ablation.

Major finding: Overall survival at 1, 3, and 5 years was 97.6%, 83.6%, and 71.5%, respectively, for the hepatic resection patients, vs 89.4%, 58.5%, and 48.8%, respectively, for the percutaneous ablation patients (P = 0.032). Recurrence-free survival at these time points was 77.6%, 47.9%, and 42.6%, respectively, for the hepatic resection group, and 40.5%, 23.2%, and 15.4%, respectively, for the percutaneous ablation group (P = 0.010). 

Study details: The data come from a retrospective study of 67 adults with resectable caudate HCC within Milan criteria at three centers; 46 underwent hepatic resection and 21 underwent percutaneous ablation.

Disclosures: The study was supported by the National Science Fund for Distinguished Young Scholars, the National Natural Science Foundation of China, and the Natural Science Foundation of Guangdong, China.

Source: Xie W et al. J Gastrointest Surg. 2021 Sep 7. doi: 10.1007/s11605-021-05111-0.

Key clinical point: A total of 84% of HCC patients had at least one emergency department visit within 12 months of therapy.

Major finding: Patients with HCC experienced an average of 3.2 adverse events over a median of 9 months; the most common was pain (75%), followed by infection (39%). Infection was the most costly adverse event ($50,374), and up to 90% of costs were associated with inpatient admissions.

Study details: The data come from 322 adults with HCC who had 12 months of follow-up data available after treatment with tyrosine kinase inhibitor (TKI) monotherapy; immune checkpoint inhibitor (ICI) monotherapy; or FOLFOX combination therapy.

Disclosures: The study was supported by AstraZeneca and some coauthors are AstraZeneca employees. Lead author Dr. Lal had no financial conflicts to disclose.

Source: Lal LS et al. Cancer Rep. 2021 Sep 7. doi: 10.1002/cnr2.1504.

Key clinical point: A total of 84% of HCC patients had at least one emergency department visit within 12 months of therapy.

Major finding: Patients with HCC experienced an average of 3.2 adverse events over a median of 9 months; the most common was pain (75%), followed by infection (39%). Infection was the most costly adverse event ($50,374), and up to 90% of costs were associated with inpatient admissions.

Study details: The data come from 322 adults with HCC who had 12 months of follow-up data available after treatment with tyrosine kinase inhibitor (TKI) monotherapy; immune checkpoint inhibitor (ICI) monotherapy; or FOLFOX combination therapy.

Disclosures: The study was supported by AstraZeneca and some coauthors are AstraZeneca employees. Lead author Dr. Lal had no financial conflicts to disclose.

Source: Lal LS et al. Cancer Rep. 2021 Sep 7. doi: 10.1002/cnr2.1504.

Key clinical point: A total of 84% of HCC patients had at least one emergency department visit within 12 months of therapy.

Major finding: Patients with HCC experienced an average of 3.2 adverse events over a median of 9 months; the most common was pain (75%), followed by infection (39%). Infection was the most costly adverse event ($50,374), and up to 90% of costs were associated with inpatient admissions.

Study details: The data come from 322 adults with HCC who had 12 months of follow-up data available after treatment with tyrosine kinase inhibitor (TKI) monotherapy; immune checkpoint inhibitor (ICI) monotherapy; or FOLFOX combination therapy.

Disclosures: The study was supported by AstraZeneca and some coauthors are AstraZeneca employees. Lead author Dr. Lal had no financial conflicts to disclose.

Source: Lal LS et al. Cancer Rep. 2021 Sep 7. doi: 10.1002/cnr2.1504.

Key clinical point: Arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib was safe and effective in patients with advanced HCC.

Major finding: At one week after the aTACE plus apatinib procedure, levels of AST and ALT were significantly elevated compared with pre-treatment levels, indicating treatment response (65.84 U/L vs 54.15 U/L and 63.44 U/L vs 51.60 U/L, respectively). Median progression-free survival was 10.2 months, and median overall survival was 23.3 months, with longer survival in patients without portal vein tumor thrombus. 

Study details: The data come from 87 consecutive adults with advanced hepatocellular carcinoma who underwent arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced hepatocellular carcinoma between December 2015 and February 2017.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Li Z et al. Can J Gastroenterol Hepatol. 2021 Aug 19. doi: 10.1155/2021/5565793.

Key clinical point: Arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib was safe and effective in patients with advanced HCC.

Major finding: At one week after the aTACE plus apatinib procedure, levels of AST and ALT were significantly elevated compared with pre-treatment levels, indicating treatment response (65.84 U/L vs 54.15 U/L and 63.44 U/L vs 51.60 U/L, respectively). Median progression-free survival was 10.2 months, and median overall survival was 23.3 months, with longer survival in patients without portal vein tumor thrombus. 

Study details: The data come from 87 consecutive adults with advanced hepatocellular carcinoma who underwent arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced hepatocellular carcinoma between December 2015 and February 2017.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Li Z et al. Can J Gastroenterol Hepatol. 2021 Aug 19. doi: 10.1155/2021/5565793.

Key clinical point: Arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib was safe and effective in patients with advanced HCC.

Major finding: At one week after the aTACE plus apatinib procedure, levels of AST and ALT were significantly elevated compared with pre-treatment levels, indicating treatment response (65.84 U/L vs 54.15 U/L and 63.44 U/L vs 51.60 U/L, respectively). Median progression-free survival was 10.2 months, and median overall survival was 23.3 months, with longer survival in patients without portal vein tumor thrombus. 

Study details: The data come from 87 consecutive adults with advanced hepatocellular carcinoma who underwent arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced hepatocellular carcinoma between December 2015 and February 2017.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Li Z et al. Can J Gastroenterol Hepatol. 2021 Aug 19. doi: 10.1155/2021/5565793.